P/E at 32.64 vs Industry's 31.90: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Premium Reflects Market Nuance

The current P/E of 32.64 for Sun Pharmaceutical Industries Ltd represents a modest premium of approximately 2.3% over the industry average of 31.90. This premium suggests that investors are willing to pay slightly more for the stock relative to its sector peers, possibly reflecting expectations of stable earnings or perceived resilience in a challenging market environment. However, the premium is not excessive, indicating a valuation that remains broadly in line with sector norms. Sun Pharma’s market capitalisation stands at ₹3,96,370 crores, firmly placing it in the large-cap category within Pharmaceuticals & Biotechnology.

Given the close proximity of the stock’s P/E to the sector average, the valuation does not signal an extreme divergence but rather a cautious market stance. Sun Pharmaceutical Industries Ltd’s valuation premium invites the question: previously rated Hold, what is Sun Pharma’s current rating? The four-parameter analysis factors in this valuation nuance alongside performance and technical indicators.

Performance Across Timeframes: Mixed Momentum Signals

Examining the stock’s returns across multiple periods reveals a complex performance profile. Over the past year, Sun Pharma has declined by 2.41%, underperforming the Sensex’s 1.81% gain. This underperformance contrasts with the three-month period, where the stock’s loss of 2.15% is notably less severe than the Sensex’s 6.30% decline, indicating relative resilience in the near term.

Shorter-term returns paint a more challenging picture. The one-month performance shows a decline of 7.58%, significantly lagging the Sensex’s 4.78% gain, while the one-week return is down 2.89% against the Sensex’s 0.73% rise. The stock’s one-day gain of 0.73% slightly outpaced the Sensex’s 1.66% advance, marking a modest rebound after two consecutive days of losses.

Year-to-date, the stock has fallen 3.24%, outperforming the Sensex’s sharper 8.32% decline. Longer-term returns remain robust, with three-year gains of 65.77% and five-year gains of 162.90%, both comfortably ahead of the Sensex’s respective 29.28% and 60.08%. However, the ten-year return of 100.06% trails the Sensex’s 204.86%, reflecting a more moderate growth trajectory over the last decade. Is this short-term weakness a temporary setback or indicative of deeper challenges?

Moving Average Configuration: Bearish Technical Setup Persists

The technical picture for Sun Pharmaceutical Industries Ltd remains subdued. The stock is trading below all key moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This configuration typically signals a bearish trend or at least a lack of upward momentum in the near to medium term.

Being below the short-term averages such as the 5-day and 20-day moving averages suggests recent price weakness, while trading below the longer-term averages like the 100-day and 200-day indicates that the stock has not yet entered a sustained recovery phase. The absence of any crossover above these averages means the stock remains in a downtrend or consolidation phase. The 5-day surge of 0.73% after two days of losses partially reverses recent declines — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has experienced a varied performance landscape recently. While some stocks have posted gains, others have remained flat or declined, reflecting ongoing sector-specific challenges such as regulatory scrutiny, pricing pressures, and global supply chain disruptions. Sun Pharma’s relative outperformance in the three-month and year-to-date periods compared to the Sensex suggests it has weathered some of these headwinds better than the broader market, though its underperformance over the one-month and one-year periods indicates persistent hurdles.

Within this mixed sector environment, the stock’s valuation premium and technical weakness highlight the tension between market expectations and recent price action. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Hold, Now Reassessed

On 23 Feb 2026, Sun Pharmaceutical Industries Ltd’s rating was updated from Hold, reflecting a reassessment of its fundamentals, valuation, and technical outlook. The previous Mojo Score was 72.0, indicating a solid standing within its sector. This rating change coincides with the stock’s current valuation premium and mixed performance signals, underscoring the complexity of its investment profile.

The reassessment suggests that while the stock’s fundamentals remain robust enough to warrant attention, the recent price action and technical indicators require careful monitoring. What is the current rating for Sun Pharmaceutical Industries Ltd following this update?

Conclusion: Data Reflects a Stock at a Crossroads

The data for Sun Pharmaceutical Industries Ltd reveals a stock trading at a slight valuation premium relative to its sector, with a mixed performance record across timeframes. While longer-term returns remain strong, recent months have seen underperformance against the Sensex, tempered by relative resilience in the three-month and year-to-date periods.

The technical setup remains bearish, with the stock below all major moving averages, indicating that any short-term rallies should be viewed cautiously. The sector’s mixed results add further complexity to the picture, as does the recent rating reassessment from Hold. Collectively, these data points portray a stock at a crossroads, balancing valuation expectations against performance and technical realities.

Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →